Omnipaque is a world-leading contrast agent for X-ray and has been used in more than 350 million patients worldwide (2). Its indications for oral use include arthrography, examination of the ...
Iohexol 755mg (equivalent to 350mg of organic iodine) per mL; soln; preservative-free. IV administration: in adults, for angiocardiography (ventriculography, selective coronary arteriography), ...
Iohexol 518mg (equivalent to 240mg of organic iodine) per mL; soln; preservative-free. Intrathecal administration: in adults, for myelography (lumbar, thoracic, cervical, total columnar) and ...
Amneal Pharmaceuticals announced that the U.S. FDA has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque, with plans to launch in the first ...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol ...
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's ...
Disruptions to the global supply chain, greatly intensified since the start of the pandemic, have affected multiple industries including the health care sector, which is currently suffering from ...
Omnipaque, or iohexol, is a type of intravenous contrast dye used regularly in CT scans to better see clots or tumors. Supplies have tightened as overseas makers struggle with COVID, creating concerns ...
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results